Eu2P

Description

Decision making on medicines informed by quantitative benefit-risk assessment may differ depending on the perspective of the decision maker and the phase of drug development. This module will address the decision-making on medicines by different stakeholders and how to apply advanced benefit-risk assessment tools in this process. Topics covered include: Multi-criteria decision analysis Conjoint analysis Personalized benefit-risk assessment

IMI Standards

• A predefined set of teaching objectives, leading to defined learning outcomes
• Assessment of the students' achievement in accordance with the agreed learning outcomes of the training offered
• A system for collecting, assessing and addressing feedback from learners, teachers, technical / administrative staff and programme / course / module managers
• Availability of appropriate and regularly reviewed reference material (e.g. published articles, links, book chapters, scripts, etc)
• Defined and transparent admission criteria
• Quality assurance of teaching staff
• Regular review of the QA/QC process and demonstration that the training is further developed in light of this review
• The facilities, infrastructure, leadership and competences available for the support of student learning
• University accreditation OR a system for approving, monitoring and reviewing the training offered